A Narrative Review of the Prognostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Cardiovascular Disease.

IF 2.7 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Angiology Pub Date : 2026-09-26 DOI:10.1177/00033197261489648

Georgios V Tsamourlidis, Dimitrios A Chatzelas, Apostolos G Pitoulias, Theodosia N Zampaka, Maria D Tachtsi, Anastasios G Potouridis, Georgios A Pitoulias

{"title":"A Narrative Review of the Prognostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Cardiovascular Disease.","authors":"Georgios V Tsamourlidis, Dimitrios A Chatzelas, Apostolos G Pitoulias, Theodosia N Zampaka, Maria D Tachtsi, Anastasios G Potouridis, Georgios A Pitoulias","doi":"10.1177/00033197261489648","DOIUrl":null,"url":null,"abstract":"<p><p>The soluble urokinase-type plasminogen activator receptor (suPAR) is a promising biomarker associated with various clinical entities. This review considers the association between suPAR and cardiovascular (CV) disease (CVD). We conducted a comprehensive electronic search of the literature on suPAR and CVD. PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library were searched from inception to December 31, 2025. Raised suPAR levels are independently associated with atherosclerosis, coronary artery disease, myocardial infarction, peripheral arterial disease (PAD) and related events and overall CV mortality. suPAR reflects inflammatory pathways distinct from those captured by C-reactive protein and is less affected by anthropometric parameters. suPAR levels correlate with endothelial dysfunction, the severity and extent of PAD and coronary artery calcium score, plaque inflammation and neointima hyperplasia. The variant rs4760 of the Plasminogen Activator, Urokinase Receptor gene that encodes suPAR may promote atherosclerosis. Lifestyle interventions and pharmacologic therapies may reduce suPAR levels. suPAR represents a robust biomarker with the potential to enhance personalized management of CVD. Despite strong evidence supporting its prognostic value, the clinical integration of suPAR remains limited. Future research should investigate its utility in risk stratification, monitoring of therapeutic response, and perioperative CV risk assessment.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"33197261489648"},"PeriodicalIF":2.7000,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197261489648","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

The soluble urokinase-type plasminogen activator receptor (suPAR) is a promising biomarker associated with various clinical entities. This review considers the association between suPAR and cardiovascular (CV) disease (CVD). We conducted a comprehensive electronic search of the literature on suPAR and CVD. PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library were searched from inception to December 31, 2025. Raised suPAR levels are independently associated with atherosclerosis, coronary artery disease, myocardial infarction, peripheral arterial disease (PAD) and related events and overall CV mortality. suPAR reflects inflammatory pathways distinct from those captured by C-reactive protein and is less affected by anthropometric parameters. suPAR levels correlate with endothelial dysfunction, the severity and extent of PAD and coronary artery calcium score, plaque inflammation and neointima hyperplasia. The variant rs4760 of the Plasminogen Activator, Urokinase Receptor gene that encodes suPAR may promote atherosclerosis. Lifestyle interventions and pharmacologic therapies may reduce suPAR levels. suPAR represents a robust biomarker with the potential to enhance personalized management of CVD. Despite strong evidence supporting its prognostic value, the clinical integration of suPAR remains limited. Future research should investigate its utility in risk stratification, monitoring of therapeutic response, and perioperative CV risk assessment.

查看原文本刊更多论文

可溶性尿激酶型纤溶酶原激活物受体（suPAR）在心血管疾病中的预后价值综述

可溶性尿激酶型纤溶酶原激活物受体（suPAR）是一种与多种临床实体相关的有前景的生物标志物。这篇综述考虑了suPAR与心血管（CV）疾病（CVD）的关系。我们对suPAR和CVD的文献进行了全面的电子检索。PubMed/MEDLINE、Scopus、Web of Science和Cochrane Library从成立到2025年12月31日进行了检索。suPAR水平升高与动脉粥样硬化、冠状动脉疾病、心肌梗死、外周动脉疾病（PAD）及其相关事件和总体CV死亡率独立相关。suPAR反映了不同于c反应蛋白捕获的炎症途径，受人体测量参数的影响较小。suPAR水平与内皮功能障碍、PAD的严重程度和范围、冠状动脉钙评分、斑块炎症和新生内膜增生有关。编码suPAR的纤溶酶原激活物尿激酶受体基因变异rs4760可能促进动脉粥样硬化。生活方式干预和药物治疗可降低suPAR水平。suPAR是一种强大的生物标志物，具有增强心血管疾病个性化管理的潜力。尽管有强有力的证据支持其预后价值，但suPAR的临床整合仍然有限。未来的研究应探讨其在风险分层、治疗反应监测和围手术期心血管风险评估中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Angiology 医学-外周血管病

CiteScore

5.50

自引率

14.30%

发文量

180

审稿时长

6-12 weeks

期刊介绍： A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days